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Abstract. Pottegard A, Hallas J, Olesen M, Svendsen
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Oakland, CA, USA; Danish Cancer Society,
Copenhagen, Denmark). Hydrochlorothiazide use
is strongly associatedwith risk of lip cancer. J Intern
Med 2017; 282: 322–331.
Background. The diuretic hydrochlorothiazide is
amongst the most frequently prescribed drugs in
the United States and Western Europe, but there is
suggestive evidence that hydrochlorothiazide use
increases the risk of lip cancer.
Objectives. To study the association between use of
hydrochlorothiazide and squamous cell carcinoma
of the lip.
Methods. We conducted a case–control study using
Danish nationwide registry data. From the Cancer
Registry (2004–2012), we identified 633 case
patients with squamous cell carcinoma (SCC) of
the lip and matched them to 63 067 population
controls using a risk-set sampling strategy.
Hydrochlorothiazide use (1995–2012) was obtained
from the Prescription Registry and defined accord-
ing to cumulative use. Applying conditional logistic
regression, we calculated odds ratios (ORs) for SCC
lip cancer associated with hydrochlorothiazide use,
adjusting for predefined potential confounders
obtained from demographic, prescription and
patient registries.
Results. Ever-use of hydrochlorothiazide was associ-
ated with an adjusted OR for SCC lip cancer of 2.1
(95%confidence interval (CI): 1.7–2.6), increasing to
3.9 (95%CI: 3.0–4.9) for high use (≥25 000 mg).
There was a clear dose–response effect (P < 0.001),
with the highest cumulative dose category of
hydrochlorothiazide (≥100 000 mg) presenting an
OR of 7.7 (95%CI: 5.7–10.5). No association with lip
cancer was seen with use of other diuretics or
nondiuretic antihypertensives. Assuming causality,
we estimated that 11% of the SCC lip cancer cases
could be attributed to hydrochlorothiazide use.
Conclusions. Hydrochlorothiazide use is strongly
associated with an increased risk of lip cancer.
Keywords: cancer, epidemiology,hydrochlorothiazide,
pharmacology.
Introduction
The diuretic hydrochlorothiazide (HCTZ) is
amongst the most frequently prescribed drugs in
the United States (US) and Western Europe [1, 2].
In the United States alone, more than 10 million
patients annually use HCTZ [2]. It has primarily
been employed as a first-line treatment for hyper-
tension, often in combination with other antihy-
pertensive drugs, but is also used for oedema and
congestive heart failure.
In a screening study from 2009, Friedman and
colleagues performed an exploratory study,
identifying a potential association between HCTZ
and lip cancer [3]. This signal was later refined in a
tailored analysis, suggesting a fourfold increased
lip cancer risk with ≥5 years of HCTZ use [4]. Sun
exposure is the predominant risk factor for lip
cancer, and the photosensitizing properties of
HCTZ [5] could explain its link to lip cancer. In
2013, the International Agency for Research on
Cancer (IARC) classified HCTZ as ‘possibly car-
cinogenic to humans’ (Group 2B) [6], based par-
tially on the lip cancer findings [4] and
accumulating laboratory and epidemiologic evi-
dence linking drug-induced photosensitivity to
skin cancer [7–9].
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Original Article
We recently reported the results of a screening
study of drug–cancer associations [10]. Herein, we
observed an association between use of a combined
preparation of HCTZ and amiloride and increased
risk of squamous cell carcinoma (SCC) of the lip.
This finding, together with the sparse epidemio-
logic evidence of an association between HCTZ use
and lip cancer [4] and the request for further
studies of drugs classified as potentially carcino-
genic by the IARC [11], prompted us to conduct
more extensive analyses of the association between
HCTZ use and risk of SCC lip cancer using detailed
data from the Danish nationwide registries.
Materials and methods
We conducted a nested case–control analysis of
nationwide registry data comparing HCTZ use
amongst patients diagnosed with SCC of the lip
(cases) with use amongst cancer-free persons
(controls) to estimate odds ratios (ORs) for SCC
lip cancer associated with HCTZ use. We obtained
data from five nationwide registry sources: the
Danish Cancer Registry [12], Danish National
Prescription Registry [13], Danish National Patient
Registry [14], Danish Education Registries [15] and
Danish Civil Registration System [16, 17]. The
Supplementary Material provides a detailed
description of the registries (Appendix S1) with
codes for tumour characteristics, drug exposure
and covariates (Appendix S2).
Case selection
Cases were all Danish residents with a biopsy-
verified first diagnosis of SCC of the lip between 1
January 2004 and 31 December 2012. Cases had
no history of cancer (except nonmelanoma skin
cancer) prior to the lip cancer diagnosis (index
date), were continuous residents in Denmark for at
least 10 years prior to the index date and had no
record of organ transplantation, azathioprine use
or diagnoses of HIV or AIDS (because of the
association between immunosuppression and skin
cancer) [18–21].
Control selection
For each case, using a risk-set sampling strategy,
we selected 100 controls amongst all Danish res-
idents matched by sex and birth year, applying the
same exclusion criteria as for cases. The index
dates used for controls were identical to the dates
of the corresponding cases. Persons were eligible as
controls before they became cases. Therefore, the
calculated ORs provide unbiased estimates of the
incidence rate ratios that would have emerged from
a cohort study based on the source population [22].
Exposure assessment
Ever-use of HCTZ was defined as having filled at
least one prescription for a HCTZ-containing drug
prior to the index date; never-use was defined as no
such prescriptions. In Denmark, HCTZ is pre-
scribed almost exclusively in combination prepa-
rations with nondiuretic antihypertensives or with
the potassium-sparing diuretic amiloride. We
defined high use of HCTZ as filled prescriptions
equivalent to ≥25 000 mg of HCTZ, corresponding
to approximately 3 years of cumulative use (1000
defined daily doses [23]).
Prescriptions filled within 2 years before the index
date (lag-time) were disregarded to allow a reason-
able induction period for an effect on lip cancer risk
and to guard against the possibility that increased
medical attention before the cancer diagnosis
influenced prescribing of HCTZ, introducing
‘reverse causation’ [24]. In sensitivity analyses,
we varied the length of the lag-time.
Analytical variables
We based potential confounder selection on data
available in nationwide prescription, patient and
education registries: (i) use of selected drugs with
suggested photosensitizing properties, including
oral retinoids, topical retinoids, tetracycline,
macrolides, aminoquinolines and amiodarone [9,
25–27]; (ii) use of drugs with suggested cancer
chemopreventive effects, including aspirin, nonas-
pirin nonsteroidal anti-inflammatory drugs
(NSAIDs) and statins [11]; (iii) history of diabetes,
chronic obstructive pulmonary disease (COPD) and
conditions associated with heavy alcohol con-
sumption, derived from composite measures of
hospital diagnoses and prescription use of dis-
ease-specific drugs (see Appendix S2); (iv) history
of nonmelanoma skin cancer; (v) average Charlson
Comorbidity Index (CCI) scores [28, 29] (0 low; 1–2:
medium; or ≥3: high), derived from diagnoses of 19
chronic conditions; and (vi) highest achieved edu-
cation (short; medium; higher; unknown) as a
measure of socio-economic status. Exposure to
each potential confounder drug was defined as two
or more prescriptions on separate dates, and
hospital histories of each of the selected conditions
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were defined as a primary or secondary discharge
or ambulatory diagnosis. As for HCTZ use, we
disregarded covariate information recorded less
than 2 years prior to the index date.
Main analyses
The analysis followed a conventional matched
case–control approach. We computed the fre-
quency and proportion of cases and controls within
categories of the exposure and covariates. Using
conditional logistic regression analysis, we com-
puted ORs with 95% confidence intervals (CIs) for
SCC lip cancer associated with HCTZ use whilst
adjusting for the predefined potential confounders.
The effect of age and sex was handled by the
matching and conditional analysis. Additionally, to
examine a potential dose–response relationship,
we performed analyses stratified according to pre-
defined categories of cumulative HCTZ use. A
formal dose–response analysis was performed by
restricting analyses to ever-users and estimating
the incremental OR for each 25 000 mg HCTZ
(capping exposure at 100 000 mg), using ordinary
logistic regression whilst also adjusting for sex and
age as a continuous variable. Never-use served as
the reference group for all analyses unless stated
otherwise.
To estimate the proportion of SCC lip cancer cases
that, during our study period, could be attributed to
use of HCTZ, we calculated the ‘population-level
attributable proportion’ (APpop) using the follow-
ing equation: APpop = propcases  (OR-1)/OR. Here,
propcases denotes theproportionof all SCC lip cancer
cases classified as exposed to high use of HCTZ. The
applied ORwas that obtained for themain analysis,
that is the fully adjusted association between high
use of HCTZ and SCC lip cancer.
Secondary and sensitivity analyses
We performed a number of preplanned subanaly-
ses. First, we defined HCTZ use according to
duration and intensity of use, assuming that the
number of tablets represented the number of days
that HCTZ was taken (whilst not allowing stockpil-
ing). For intensity of use, we estimated the average
daily dose of HCTZ as the total amount of drug
filled (summing defined daily doses) divided by the
estimated cumulative duration of use. Secondly,
we performed subgroup analyses according to age
and sex or with restriction to specific subsets of the
study population: never-user of other
photosensitizing drugs (as defined above); low
comorbidity (CCI score = 0); no history of diabetes;
or no history of nonmelanoma skin cancer. Thirdly,
we repeated the main analyses for bendroflume-
thiazide, besides HCTZ the most frequently pre-
scribed thiazide in Denmark, and for the loop
diuretic furosemide that has been suggested to
possess photosensitizing properties [9, 25–27]. In
dose–response analyses of bendroflumethiazide,
we used dose categories that were 10 times lower
than for HCTZ because bendroflumethiazide is
considered to be about 10 times as potent [30,
31]. We also performed analyses for antihyperten-
sives with similar indications to thiazides (that is
primarily mild to moderate hypertension), includ-
ing angiotensin-converting enzyme (ACE) inhibi-
tors, angiotensin II (ATII) antagonists and group 2
calcium-channel blockers (CCBs). Amongst CCBs,
we excluded nifedipine that possesses photosensi-
tizing properties and has been associated with an
increased risk of lip cancer [4]. In Denmark,
however, nifedipine prescriptions only comprise
only 1.8% of the total sales of CCBs [32], preclud-
ing meaningful analyses of this drug. In analyses of
other diuretics and nondiuretic antihypertensives,
associations were adjusted for HCTZ use. Fourthly,
we restricted HCTZ use to combination therapy
with amiloride, which generated the ‘drug–cancer
signal’ with lip cancer in our recent screening study
[10]. Fifthly, we excluded ever-users of amiloride
from the main analyses to obtain ORs for SCC lip
cancer associated with HCTZ use exclusive of
amiloride use. Finally, we repeated the main anal-
yses varying the lag-time between 0 and 5 years (in
steps of 6 months).
Other
All analyses were performed using STATA Release
14.1 (StataCorp, College Station, TX, USA). The
Danish Data Protection Agency and Statistics
Denmark’s Scientific Board approved the study.
According to Danish law, ethical approval is not
required for registry-based studies.
Results
Main analysis
After exclusions (n = 222), the study population
comprised 633 biopsy-verified SCC cases (Fig. 1)
matched to 63 067 cancer-free controls. Cases had
higher comorbidity and lower educational status
than controls (Table 1). The remaining character-
istics were similar amongst cases and controls.
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Hydrochlorothiazide was obtained mainly in com-
bination with ATII antagonists (44% of all prescrip-
tions filled amongst controls), amiloride (33%) and
ACE inhibitors (21%). Overall, 14.8% of cases and
4.4% of controls were high-users (≥25 000 mg) of
HCTZ, yielding an adjusted OR for SCC lip cancer
of 3.9 (95%CI: 3.0–4.9). Analyses defining HCTZ
use according to cumulative amount showed a
clear dose–response pattern, with high ORs in both
the predefined (≥50 000 mg: 5.5; 95%CI: 4.2–7.2)
and post hoc (≥100 000 mg: 7.7; 95%CI: 5.7–10.5)
upper exposure categories (Table 2). In the dose–
response analysis, the incremental OR per
25 000 mg HCTZ was 1.7 (95%CI: 1.5–1.9,
P < 0.001). Analyses defining HCTZ use according
to duration or intensity also revealed clear trends
towards higher values in the upper exposure
categories (duration ≥5 years: OR, 4.5; 95%CI:
3.5–5.9; intensity ≥32.25 mg day1: OR, 4.9; 95%
CI: 3.0–7.8) (Table 3). The estimation of the ‘pop-
ulation-level attributable proportion’ (APpop)
yielded a value of 0.11; equivalent to 11% of all
SCC lip cancer cases occurring during the study
period could be attributed to high use of HCTZ
(assuming causality).
Incident SCC lip
cancer cases during
2004–2012:
855 cases
Final case populaon:
633 cases
No histological diagnosis
- 88 cases
Previous cancer
- 111 cases
Migraon
- 9 cases
Organ transplantaon,
use of azathioprine,
or HIV diagnosis
- 14 cases
Fig. 1 Flow chart of case selection.
Table 1 Characteristics of lip cancer cases and matched
controls
Cases Controls
(n = 633) (n = 63 067)
Age, median (IQR) 72 (64–80) 72 (64–80)
Male 426 (67.3%) 42 499 (67.4%)
Use of HCTZ
Never-use 494 (78.0%) 55 666 (88.3%)
Ever-use 139 (22.0%) 7401 (11.7%)
High use 94 (14.8%) 2771 (4.4%)
Use of photosensitizing drugs
Any 309 (48.8%) 27 819 (44.1%)
Topical retinoids 12 (1.9%) 1183 (1.9%)
Oral retinoids 5 (0.8%) 1255 (2.0%)
Tetracycline 29 (4.6%) 3084 (4.9%)
Macrolides 269 (42.5%) 23 729 (37.6%)
Aminoquinolines 114 (18.0%) 9581 (15.2%)
Amiodarone 7 (1.1%) 1596 (2.5%)
Other drug use
Aspirin 185 (29.2%) 17 881 (28.4%)
Nonaspirin NSAIDs 340 (53.7%) 32 610 (51.7%)
Statins 136 (21.5%) 12 888 (20.4%)
Diagnoses
Alcohol-associated
conditions
28 (4.4%) 2128 (3.4%)
Diabetes 66 (10.4%) 5116 (8.1%)
COPD 47 (7.4%) 3675 (5.8%)
CCI score
0 374 (59.1%) 41 872 (66.4%)
1 138 (21.8%) 11 835 (18.8%)
2 58 (9.2%) 5044 (8.0%)
≥3 63 (10.0%) 4316 (6.8%)
Education
Short 321 (50.7%) 24 431 (38.7%)
Medium 171 (27.0%) 21 796 (34.6%)
Long 75 (11.8%) 10 882 (17.3%)
Unknown 66 (10.4%) 5958 (9.4%)
HCTZ, hydrochlorothiazide; IQR, interquartile range;
COPD, chronic obstructive pulmonary disease; CCI,
Charlson Comorbidity Index.
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Secondary and sensitivity analyses
In secondary analyses of high-use HCTZ, only
minor variations in ORs were seen according to
age or sex or within the selected subgroups of
study subjects (Table 4). In general, the adjust-
ment for potential confounders had limited influ-
ence on the OR estimates (Table S1).
In analyses of bendroflumethiazide or CCB use, we
found no apparent associations with SCC lip
cancer risk, overall or according to cumulative
amount, duration or intensity of use (Table 5).
Similarly, we observed no associations for SCC lip
cancer with use of ACE inhibitors, ATII antagonists
or furosemide (Table S2a–c).
Individual analyses of amiloride was not feasible,
because almost all (>99%) amiloride was prescribed
in combination with HCTZ. Excluding ever-users of
amiloride, we observed a dose–response pattern for
HCTZ use similar to the main analysis, that is a
neutral OR for SCC lip cancer with a cumulative
amount <25 000 mg (ORs 1.0–1.1), increasing to
ORs of 1.7 (95%CI: 1.0–2.9) and 2.4 (95%CI: 1.0–
5.8) for25 000–49 000 mgand50 000–74 999 mg,
respectively. We could not estimate associations for
a cumulative amount above 75 000 mg, as subjects
with highest use of HCTZ had predominantly used
the HCTZ–amiloride combination.
In analyses varying the lag-time prior to the index
date, we found increasing ORs for SCC lip cancer
with increasing lag-time for HCTZ exposure, from
3.1 (95%CI: 2.5–3.9) with no lag-time to 5.3 (95%
CI: 4.1–6.7) with 5 years of lag-time (Table S3). The
(null) association between bendroflumethiazide
use and SCC lip cancer risk did not vary according
to length of lag-time (data not shown).
Discussion
In this nationwide case–control study, use of the
photosensitizing diuretic HCTZ was associated
with a substantially increased risk of SCC of the
lip. Risk increased with increasing cumulative
amount, duration and intensity of HCTZ use. More
than 100 000 mg of HCTZ, corresponding to more
than 10 years of cumulative use, was associated
with a sevenfold increased risk for SCC lip cancer.
Assuming causality, an estimated 11% of all SCC
lip cancer cases occurring the study period could
Table 2 Association between exposure to hydrochlorothiazide and risk of squamous cell carcinoma of the lip, according to
cumulative amount of hydrochlorothiazide use
Subgroup Cases Controls Crude ORa Adjusted ORb
Nonuse 494 55 666 1.0 (ref.) 1.0 (ref.)
Ever-use 139 7401 2.2 (1.8–2.6) 2.1 (1.7–2.6)
High use (≥25 000 mg) 94 2771 4.0 (3.2–5.0) 3.9 (3.0–4.9)
Cumulative amount
1–4999 mg 16 1745 1.0 (0.6–1.7) 1.0 (0.6–1.7)
5000–9999 mg 12 1083 1.2 (0.7–2.2) 1.2 (0.7–2.2)
10 000–24 999 mg 17 1802 1.1 (0.7–1.7) 1.1 (0.7–1.7)
25 000–49 999 mg 20 1253 1.9 (1.2–2.9) 1.8 (1.2–2.9)
≥50 000 mg 74 1518 5.8 (4.5–7.5) 5.5 (4.2–7.2)
Post hoc categoriesc
50 000–74 999 mg 12 460 3.0 (1.7–5.4) 2.9 (1.6–5.3)
75 000–99 999 mg 8 254 3.7 (1.8–7.5) 3.4 (1.7–7.0)
≥100 000 mg 54 804 8.2 (6.1–11.1) 7.7 (5.7–10.5)
aAdjusted for age, gender and calendar time (by risk-set matching and conditional analysis). bFully adjusted model,
additionally adjusted for (i) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines and
amiodarone; (ii) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs or statins; (iii) history of heavy alcohol
consumption, diabetes or chronic obstructive pulmonary disease; (iv) history of nonmelanoma skin cancer; (v) Charlson
Comorbidity Index score (0: low; 1–2: medium; or ≥3: high); and (vi) highest achieved education (short, medium, long or
unknown). cPerformed as post hoc analyses due to the unexpectedly large number of cases in the highest of the predefined
exposure categories (≥50 000 mg).
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be attributed to use of HCTZ. Meanwhile, use of the
diuretics bendroflumethiazide or furosemide or
nondiuretic antihypertensive drugs was not asso-
ciated with increased lip cancer risk.
The strengths of our study are its national scale and
large population, long study period and high-
quality registry data with lip cancer diagnoses
restricted to histologically verified SCC cases iden-
tified from the Danish Cancer Registry, which is
known to have accurate and virtually complete
registration of incident cancers in Denmark [12].
The use of the Danish Prescription Registry also
ensured complete and high-quality assessment of
drug use with up to 18 years of exposure history
[13]. Themain limitation was lack of information on
UV exposure and tobacco smoking, the two major
risk factors for lip cancer. However, we find it
unlikely that HCTZ users would have markedly
different sun exposure or smoking patterns than
never-users. To reduce partially potential con-
founding by tobacco smoking, we adjusted for
COPD as a crude measure of heavy smoking. We
also adjusted for both individual chronic diseases
and general comorbidity, estimated by average CCI
scores. Differences in comorbidity might introduce
bias if medical attention and thus diagnostic
opportunity for lip cancer were higher amongst
HCTZ users because of higher comorbidity than
amongst never-users of HCTZ. However, such
surveillance bias is unlikely to occur specifically
amongst HCTZ users and not amongst users of
other antihypertensive drugs. Notwithstanding the
possibility of residual confounding by sun exposure
or tobacco smoking, differences in these risk factors
according to HCTZ use would need to be extremely
large to account for the up to sevenfold increased
ORs observed in our study.
Our findings are compatible with the results
reported by Friedman et al. who found that
≥5 years of cumulative HCTZ use was associated
with an OR for lip cancer of 4.22 (95%CI: 2.82–
6.31) [4]. The authors observed similar results for
HCTZ monotherapy. We could not evaluate associ-
ation for HCTZ monotherapy, because in Denmark
nearly all HCTZ was prescribed as a combination
preparation with amiloride or with nondiuretic
Table 3 Association between exposure to hydrochlorothiazide and risk of squamous cell carcinoma of the lip, according to
cumulative duration and intensity of hydrochlorothiazide use
Subgroup Cases Controls Crude ORa Adjusted ORb
Nonuse 494 55 666 1.0 (ref.) 1.0 (ref.)
Cumulative duration of usec
0–1 year 22 2365 1.1 (0.7–1.6) 1.0 (0.7–1.6)
1–2 years 13 1091 1.3 (0.7–2.3) 1.3 (0.7–2.2)
2–3 years 5 821 0.7 (0.3–1.7) 0.7 (0.3–1.7)
3–5 years 25 1256 2.3 (1.5–3.5) 2.3 (1.5–3.4)
5+ years 74 1868 4.7 (3.6–6.0) 4.5 (3.5–5.9)
Intensity of use amongst high-usersd
6.25 mg day1 (n < 5) (n < 5) (-) (-)
12.5 mg day1 13 672 2.3 (1.3–4.0) 2.3 (1.3–4.0)
18.75 mg day1 5 153 4.0 (1.6–9.9) 3.8 (1.5–9.5)
25 mg day1 44 745 7.0 (5.1–9.8) 6.7 (4.8–9.3)
≥32.25 mg da1y 20 448 5.4 (3.4–8.5) 4.9 (3.0–7.8)
aAdjusted for age, gender and calendar time (by risk-set matching and conditional analysis). bFully adjusted model,
additionally adjusted for (i) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines and
amiodarone; (ii) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs or statins; (iii) history of heavy alcohol
consumption, diabetes or chronic obstructive pulmonary disease; (iv) history of nonmelanoma skin cancer; (v) Charlson
Comorbidity Index score (0: low; 1–2: medium; or ≥3: high); and (vi) highest achieved education (short, medium, long or
unknown). cThe duration of use assigned to each prescription was estimated assuming an intake of one tablet daily whilst
not allowing stockpiling. dRestricted to those with high use of hydrochlorothiazide (≥25 000 mg). Intensity of use was
estimated by dividing the total amount of drug filled with the estimated cumulative duration of use, whilst rounding to the
nearest value of the categories.
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antihypertensives. Theoretically, amiloride use
could have contributed to the increased risk
observed with overall use of HCTZ, but current
evidence rather suggests that amiloride may pos-
sess antineoplastic effects [33]. Furthermore, a
similar dose–response pattern for HCTZ was
observed in our study when use of amiloride was
excluded. To our knowledge, the association
between HCTZ use and lip cancer risk has hitherto
only been specifically addressed in the study by
Friedman et al. [4]. However, several epidemiolog-
ical studies of various photosensitizing diuretics,
including HCTZ, have indicated that HCTZ use
may increase skin cancer risk [6, 8, 9, 26, 27, 34],
notably for SCC, but results are inconsistent [6, 9].
HCTZ use was common in a US case series of
patients with a history of multiple SCCs [35], and
experimental data support a carcinogenic potential
of HCTZ [5–7]. The hypothesis is that HCTZ and
other drugs with photosensitizing properties may
influence cancer risk at sun-exposed sites and may
also induce a chronic inflammatory reaction [5, 6].
We found no association between bendroflumethi-
azide use and lip cancer risk, even with high
cumulative use. An explanation for this seemingly
inconsistent risk pattern for photosensitizing
drugs within the same chemical class [23] would
be that the photosensitizing effect varies with the
molar concentrations of the drug independently of
its diuretic action. In cell and mouse models,
bendroflumethiazide has similar photosensitizing
properties as HCTZ at equimolar concentrations
[30, 31]. However, bendroflumethiazide is a much
more potent diuretic and is typically used at 10
times lower doses and has a threefold shorter half-
life [36, 37], thus resulting in an overall 30-fold
lower molar concentration at therapeutically equiv-
alent doses.
Conclusion
We found a strong association between HCTZ use
and SCC of the lip. The high odds ratios, evidence
of specificity for HCTZ use compared to use of other
Table 4 Associations between high use of hydrochlorothiazide (≥25 000 mg) and risk of squamous cell carcinoma of the lip,
according to patient subgroups
Subgroup
Cases exposed /
unexposed
Controls exposed /
unexposed Crude ORa Adjusted ORb
Age group
<60 years 8/81 131/8943 7.4 (3.4–16.0) 6.7 (2.9–15.1)
60–75 years 34/239 1141/25 561 3.2 (2.2–4.7) 3.2 (2.2–4.7)
75+ years 52/174 1499/21 162 4.3 (3.1–5.9) 4.2 (3.0–5.9)
Gender
Male 39/356 1507/38 008 2.8 (2.0–4.0) 2.9 (2.0–4.0)
Female 55/138 1264/17 658 5.8 (4.2–8.1) 5.4 (3.9–7.6)
Other
No use of
photosensitizing
drugsc
40/260 1298/31 598 4.1 (2.9–5.8) 4.2 (2.9–6.1)
No previous NMSC 91/478 2701/54 806 4.0 (3.2–5.1) 3.9 (3.1–5.0)
CCI score = 0 53/297 1461/37 843 4.8 (3.6–6.6) 4.5 (3.3–6.3)
No diabetics 81/448 2232/51 810 4.3 (3.4–5.6) 4.2 (3.3–5.5)
CCI, Charlson comorbidity index; NMSC, nonmelanoma skin cancer; aAdjusted for age, gender and calendar time (by risk-
set matching and conditional analysis). bFully adjusted model, additionally adjusted for (i) use of topical retinoids, oral
retinoids, tetracycline, macrolides, aminoquinolines and amiodarone; (ii) aspirin, nonaspirin nonsteroidal anti-
inflammatory drugs or statins; (iii) history of heavy alcohol consumption, diabetes or chronic obstructive pulmonary
disease; (iv) history of nonmelanoma skin cancer; (v) CCI score (0: low; 1–2: medium; or ≥3: high); and (vi) highest achieved
education (short, medium, long or unknown). cThis included oral retinoids, topical retinoids, tetracycline, macrolides,
aminoquinolines and amiodarone.
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diuretics or nondiuretic antihypertensives, and the
plausible biological mechanism of photosensitivity
support a causal relationship between HCTZ use
and risk of lip cancer. Given the considerable use of
HCTZ worldwide, such numbers and attributable
proportions are not negligible when drugs compa-
rable in indications and efficacy to HCTZ are
available.
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Table 5 Association between exposure to bendroflumethiazide or calcium-channel blockers and risk of squamous cell
carcinoma of the lip, according to cumulative amount of use
Subgroup Cases Controls Crude ORa Adjusted ORb
Bendroflumethiazidec
Nonuse 449 45 763 1.0 (ref.) 1.0 (ref.)
Ever-use 184 17 304 1.1 (0.9–1.3) 1.0 (0.8–1.2)
Long-term use (≥2500 mg) 71 7262 1.0 (0.8–1.3) 1.0 (0.8–1.3)
Cumulative amount
1–499 mg 50 4341 1.2 (0.9–1.6) 1.1 (0.8–1.5)
500–999 mg 27 2273 1.2 (0.8–1.8) 1.1 (0.8–1.7)
1000–2499 mg 36 3428 1.1 (0.7–1.5) 1.0 (0.7–1.4)
2500–4999 mg 29 3148 0.9 (0.6–1.4) 0.9 (0.6–1.4)
≥5000 mg 42 4114 1.0 (0.7–1.5) 1.1 (0.8–1.5)
Group 2 calcium-channel blockers, excluding nifedipined
Nonuse 496 51 915 1.0 (ref.) 1.0 (ref.)
Ever-use 137 11 152 1.3 (1.1–1.6) 1.1 (0.9–1.4)
Long-term use (≥1000 DDD) 70 5714 1.3 (1.0–1.7) 1.1 (0.8–1.5)
Cumulative amount
1–199 DDD 24 2092 1.2 (0.8–1.9) 1.0 (0.7–1.5)
200–399 DDD 14 1249 1.3 (0.7–2.1) 1.0 (0.6–1.7)
400–999 DDD 29 2097 1.4 (1.0–2.1) 1.2 (0.8–1.7)
1000–1999 DDD 19 1928 1.1 (0.7–1.7) 0.9 (0.6–1.4)
≥2000 DDD 51 3786 1.5 (1.1–2.0) 1.2 (0.9–1.6)
DDD, defined daily doses. aAdjusted for age, gender and calendar time (by risk-set matching and conditional analysis).
bFully adjusted model, additionally adjusted for (i) use of topical retinoids, oral retinoids, tetracycline, macrolides,
aminoquinolines and amiodarone; (ii) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs or statins; (iii) history of
heavy alcohol consumption, diabetes or chronic obstructive pulmonary disease; (iv) history of nonmelanoma skin cancer;
(v) Charlson Comorbidity Index score (0: low; 1–2: medium; or ≥3: high); (vi) highest achieved education (short, medium,
long or unknown); and (vii) use of hydrochlorothiazide. c2.5 mg of bendroflumethiazide is equivalent to 25 mg of
hydrochlorothiazide. dUse of calcium-channel blockers was estimated in DDD as an aggregate measure of exposure to
different calcium-channel blockers. One DDD is equivalent to, for example, 5 mg of amlodipine, 5 mg of felodipine and
10 mg of lercanidipine (see www.whocc.no/atc_ddd_index).
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